Drugs / Adipose-Derived Stromal Vascular Fraction
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05032131 | Feb → Oct 2023 | inclusion body myositis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose-Derived Stromal Vascular Fraction | “The cell treatment will be prepared from autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF) isolated by centrifugation of adipose tissue obtain by liposuction.” NCT05032131 ↗ |
| Known as | ADSVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05032131 ↗ |
| Modality | Cell therapy | “Cell Therapy for IBM by Muscle Injection of ADSVF” NCT05032131 ↗ |
| Route | Intramuscular | “3 escalating doses of ADSVF intramuscularly injected in the non-dominant forearm” NCT05032131 ↗ |